Biogen's stock rating was upgraded because new data from its experimental Alzheimer's drug, diranersen, showed patients declining more slowly across all tested doses. Truist Securities raised Biogen to Buy from Hold and lifted its price target to $235 from $190, ahead of the study readout.
The upgrade reflects optimism about Biogen's pipeline, not a new approved medicine. Diranersen is still investigational and years from any possible pharmacy shelf. For families managing dementia, the more immediate news sits elsewhere in Biogen's lineup.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What diranersen is and why analysts noticed
- The result was mixed, not a clean win
- What a stock upgrade does and does not mean for patients
- The Biogen drug you can actually get now
- How to read Alzheimer's drug headlines
- Frequently Asked Questions
What diranersen is and why analysts noticed
Diranersen (also called BIIB080) is an investigational antisense oligonucleotide — a lab-made strand of genetic material designed to lower production of tau, a protein that tangles inside brain cells in Alzheimer's disease. It is not approved by the fda for any use.
The drug was tested in CELIA, a global, randomized, double-blind, placebo-controlled Phase 2 trial. The study enrolled 416 people with mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia, according to Ionis and Biogen. Biogen has since moved the drug into registrational development, the stage that supports a future approval application.
The result was mixed, not a clean win
Here is the caveat that matters. CELIA did not meet its primary goal — a dose-dependent effect on the Clinical dementia Rating–Sum of Boxes (CDR-SB), a standard scale of memory and daily function measured at Week 76, per Biogen's topline release. Despite that miss, pre-specified secondary analyses told a more encouraging story.
Biogen reported slowed clinical decline across all doses, with the strongest signal at the lowest 60 mg dose given every 24 weeks, plus large reductions in tau measured in spinal fluid and on brain scans, presented at the AAIC conference. A missed primary endpoint is a real limitation. Secondary findings can point the way forward, but they cannot substitute for a trial hitting its main target. That is why the next step is confirmatory testing.
What a stock upgrade does and does not mean for patients
An analyst upgrade is a financial forecast, not a medical milestone. Truist and Guggenheim are predicting Biogen's share value, not certifying that diranersen works or is safe. Guggenheim reiterated a Buy rating with a $260 target, citing the same CELIA data, according to Investing.com.
For a family living with dementia, the practical takeaway is patience. Diranersen still requires registrational Phase 3 trials and regulatory review before any possible approval. Nothing about this upgrade changes what treatments are available today.
The Biogen drug you can actually get now
If you want an approved, currently available Biogen Alzheimer's treatment, that is Leqembi (lecanemab), which Biogen markets with Eisai for early Alzheimer's disease. It targets amyloid, a different Alzheimer's protein than the tau that diranersen goes after.
Real-world results add useful context. In the LEADER study presented at AAIC 2026, over an average of 17 months about 76% of early-Alzheimer's patients on Leqembi stayed stable and roughly 7% improved, per Biogen. A more convenient version may be coming: an under-the-skin starting dose is under FDA Priority Review with a decision date of August 24, 2026.
How to read Alzheimer's drug headlines
Financial and clinical news often blur together. A few checks help you separate hype from help: If you want the primary details, Biogen's CELIA topline release lays out the numbers directly.
- Ask whether the drug is FDA-approved or still investigational — diranersen is investigational.
- Notice if a trial met its primary endpoint; CELIA did not.
- Separate analyst price targets from medical evidence — they measure different things.
- Look for who was studied; CELIA enrolled people with early disease, not advanced dementia.
- Ask your neurologist what applies to your specific diagnosis before changing any plan.
Frequently Asked Questions
Can my family member take diranersen now?
No. Diranersen is investigational, has not been FDA-approved, and still needs Phase 3 trials before any possible approval.
Did the Alzheimer's study succeed?
Partly. CELIA missed its primary endpoint but showed slowed decline and lower tau in secondary analyses.
What is the difference between diranersen and Leqembi?
Diranersen targets tau and is experimental; Leqembi targets amyloid and is FDA-approved for early Alzheimer's.
